Literature DB >> 26220749

A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

Ahmed El-Shamy1, Francis J Eng1, Erin H Doyle1, Arielle L Klepper1, Xiaochen Sun2, Angelo Sangiovanni3, Massimo Iavarone3, Massimo Colombo3, Robert E Schwartz4, Yujin Hoshida2, Andrea D Branch5.   

Abstract

BACKGROUND & AIMS: Although patients infected by genotype 1b hepatitis C virus (HCV) with Q(70) and/or M(91)core gene mutations have an almost five-fold increased risk of developing hepatocellular carcinoma (HCC) and increased insulin resistance, the absence of a suitable experimental system has precluded direct experimentation on the effects of these mutations on cellular gene expression.
METHODS: HuH7 cells were treated long-term with human serum to induce differentiation and to produce a model system for testing high-risk and control HCV. For clinical validation, profiles of infected cells were compared to each other and to those of liver biopsies of patients with early-stage HCV-related cirrhosis followed prospectively for up to 23 years (n=216).
RESULTS: Long-term culture in human serum produced growth-arrested, hepatocyte-like cells whose gene profile overlapped significantly with that of primary human hepatocytes. High-risk (Q(70)/M(91)) and control (R(70)/L(91)) viruses had dramatically different effects on gene expression of these cells. The high-risk virus enhanced expression of pathways associated with cancer and type II diabetes, while the control virus enhanced pathways associated with oxidative phosphorylation. Of special clinical relevance, the transcriptome of cells replicating the high-risk virus correlated significantly with an HCC high-risk profile in patients (Bonferroni-corrected p=0.03), whereas no such association was observed for non-HCC-related clinical outcomes.
CONCLUSIONS: The cell-based system allowed direct head-to-head comparison of HCV variants, and provided experimental support for previous clinical data indicating an oncogenic effect of core gene mutations. This simple experimental system distinguished HCV variants and will enable future mechanistic analysis and exploration of interventional approaches.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Core-mutations; HCC; HCV; Human serum

Mesh:

Substances:

Year:  2015        PMID: 26220749      PMCID: PMC4654634          DOI: 10.1016/j.jhep.2015.07.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  48 in total

1.  Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.

Authors:  Svetlana Marukian; Linda Andrus; Timothy P Sheahan; Christopher T Jones; Edgar D Charles; Alexander Ploss; Charles M Rice; Lynn B Dustin
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

2.  Amino acid substitutions in the hepatitis C virus core region are associated with postoperative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma.

Authors:  Hidenori Toyoda; Takashi Kumada; Yuji Kaneoka; Atsuyuki Maeda
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

3.  Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes.

Authors:  Kui Li; Zihong Chen; Nobuyuki Kato; Michael Gale; Stanley M Lemon
Journal:  J Biol Chem       Date:  2005-02-28       Impact factor: 5.157

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2011-06       Impact factor: 2.327

6.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

7.  Biosynthesis and biochemical properties of the hepatitis C virus core protein.

Authors:  E Santolini; G Migliaccio; N La Monica
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 10.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

View more
  10 in total

1.  Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions.

Authors:  Shira Perez; Michael Gevor; Ateret Davidovich; Antony Kaspi; Katreena Yamin; Tom Domovich; Tomer Meirson; Avi Matityahu; Yehuda Brody; Salomon M Stemmer; Assam El-Osta; Izhak Haviv; Itay Onn; Meital Gal-Tanamy
Journal:  Nucleic Acids Res       Date:  2019-03-18       Impact factor: 16.971

2.  Characterization of Anti-Cancer Activities of Violacein: Actions on Tumor Cells and the Tumor Microenvironment.

Authors:  Charlotte Dahlem; Shilpee Chanda; Jan Hemmer; Hanna S Schymik; Michael Kohlstedt; Christoph Wittmann; Alexandra K Kiemer
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

Review 3.  Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.

Authors:  Simonetta Bandiera; C Billie Bian; Yujin Hoshida; Thomas F Baumert; Mirjam B Zeisel
Journal:  Curr Opin Virol       Date:  2016-10-11       Impact factor: 7.121

4.  Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients.

Authors:  Ahmed El-Shamy; Matthew Pendleton; Francis J Eng; Erin H Doyle; Ali Bashir; Andrea D Branch
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

5.  Newly discovered hepatitis C virus minicores circulate in human blood.

Authors:  Francis J Eng; Ahmed El-Shamy; Erin H Doyle; Arielle Klepper; A Scott Muerhoff; Andrea D Branch
Journal:  Hepatol Commun       Date:  2017-11-12

6.  Thioholgamide A, a New Anti-Proliferative Anti-Tumor Agent, Modulates Macrophage Polarization and Metabolism.

Authors:  Charlotte Dahlem; Wei Xiong Siow; Maria Lopatniuk; William K F Tse; Sonja M Kessler; Susanne H Kirsch; Jessica Hoppstädter; Angelika M Vollmar; Rolf Müller; Andriy Luzhetskyy; Karin Bartel; Alexandra K Kiemer
Journal:  Cancers (Basel)       Date:  2020-05-19       Impact factor: 6.639

7.  Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

Authors:  Shira Perez; Antony Kaspi; Tom Domovitz; Ateret Davidovich; Anat Lavi-Itzkovitz; Tomer Meirson; Jacinta Alison Holmes; Chia-Yen Dai; Chung-Feng Huang; Raymond T Chung; Assy Nimer; Assam El-Osta; Gur Yaari; Salomon M Stemmer; Ming-Lung Yu; Izhak Haviv; Meital Gal-Tanamy
Journal:  PLoS Genet       Date:  2019-06-19       Impact factor: 5.917

8.  Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.

Authors:  Lynnette Bhebhe; Motswedi Anderson; Sajini Souda; Wonderful T Choga; Edward Zumbika; Zachary M Shaver; Tshepiso Mbangiwa; Bonolo B Phinius; Chabeni C Banda; Pinkie Melamu; Rosemary M Musonda; Max Essex; Jason T Blackard; Sikhulile Moyo; Simani Gaseitsiwe
Journal:  BMC Infect Dis       Date:  2019-10-22       Impact factor: 3.090

9.  Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.

Authors:  Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Masahiro Kobayashi; Shunichiro Fujiyama; Yusuke Kawamura; Tetsuya Hosaka; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

Review 10.  Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.

Authors:  Thomas F Baumert; Frank Jühling; Atsushi Ono; Yujin Hoshida
Journal:  BMC Med       Date:  2017-03-14       Impact factor: 11.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.